Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study

Journal of the American Medical Directors Association

Volumn 17, Issue 1, 2016, Pages 59-64

  Shih, Chia Jen ^a,b   Chen, Hung Ta ^a,c   Kuo, Shu Chen ^a,b,d   Ou, Shuo Ming ^a,b   Chen, Yung Tai ^a,c  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c TAIPEI CITY HOSPITAL   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Diabetes mellitus; Dipeptidyl peptidase 4 inhibitor; Elderly; Major adverse cardiovascular events; Mortality

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INSULIN; LINAGLIPTIN; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; TICLOPIDINE; VILDAGLIPTIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR;

ADVERSE OUTCOME; AGE DISTRIBUTION; AGED; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR EFFECT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL PRACTICE; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG SAFETY; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; POPULATION; PRESCRIPTION; PROPENSITY SCORE; RISK ASSESSMENT; RISK FACTOR; SEX ALLOCATION; CASE CONTROL STUDY; DIABETES MELLITUS, TYPE 2; MEDICATION COMPLIANCE; MYOCARDIAL INFARCTION; STATISTICS AND NUMERICAL DATA; STROKE; TAIWAN;

AGED; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MEDICATION ADHERENCE; MYOCARDIAL INFARCTION; PROPENSITY SCORE; STROKE; TAIWAN;

EID: 84955171790     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2015.10.009     Document Type: Article

References (38)

1. 2014 National Diabetes Statistics Report. Available at:. Accessed August 4, 2015. http://www.cdc.gov/diabetes/data/statistics/2014statisticsreport.html.
2. Narayan K.M., Boyle J.P., Geiss L.S., et al. Impact of recent increase in incidence on future diabetes burden: U.S., 2005-2050. Diabetes Care 2006, 29:2114-2116.
3. Sepulveda J., Murray C. The state of global health in 2014. Science 2014, 345:1275-1278.
4. Salpeter S.J., Khalaileh A., Weinberg-Corem N., et al. Systemic regulation of the age-related decline of pancreatic beta-cell replication. Diabetes 2013, 62:2843-2848.
5. Huang E.S., Laiteerapong N., Liu J.Y., et al. Rates of complications and mortality in older patients with diabetes mellitus: The diabetes and aging study. JAMA Intern Med 2014, 174:251-258.
6. Gilbert R.E., Krum H. Heart failure in diabetes: Effects of anti-hyperglycaemic drug therapy. Lancet 2015, 385:2107-2117.
7. Huang E.S., Liu J.Y., Moffet H.H., et al. Glycemic control, complications, and death in older diabetic patients: The diabetes and aging study. Diabetes Care 2011, 34:1329-1336.
8. Inzucchi S.E., Bergenstal R.M., Buse J.B., et al. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015, 38:140-149.
9. Lakey W.C., Barnard K., Batch B.C., et al. Are current clinical trials in diabetes addressing important issues in diabetes care?. Diabetologia 2013, 56:1226-1235.
10. Cruz-Jentoft A.J., Carpena-Ruiz M., Montero-Errasquin B., et al. Exclusion of older adults from ongoing clinical trials about type 2 diabetes mellitus. J Am Geriatr Soc 2013, 61:734-738.
11. Craddy P., Palin H.J., Johnson K.I. Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: A systematic review and mixed treatment comparison. Diabetes Ther 2014, 5:1-41.
12. Schwartz S.L. Treatment of elderly patients with type 2 diabetes mellitus: A systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. Am J Geriatr Pharmacother 2010, 8:405-418.
13. Shih C.J., Chu H., Chao P.W., et al. Long-term clinical outcome of major adverse cardiac events in survivors of infective endocarditis: A nationwide population-based study. Circulation 2014, 130:1684-1691.
14. Chao P.W., Shih C.J., Lee Y.J., et al. Association of postdischarge rehabilitation with mortality in intensive care unit survivors of sepsis. Am J Respir Crit Care Med 2014, 190:1003-1011.
15. Hsing A.W., Ioannidis J.P. Nationwide population science: Lessons from the Taiwan National Health Insurance Research Database. JAMA Intern Med 2015, 175:1527-1529.
16. Lin C.C., Lai M.S., Syu C.Y., et al. Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. J Formos Med Assoc 2005, 104:157-163.
17. Leslie S.R., Gwadry-Sridhar F., Thiebaud P., Patel B.V. Calculating medication compliance, adherence and persistence in administrative pharmacy claims databases. Pharma Prog 2008, 1:13-19.
18. Benner J.S., Glynn R.J., Mogun H., et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002, 288:455-461.
19. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987, 40:373-383.
20. Chang H.Y., Weiner J.P., Richards T.M., et al. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care 2012, 18:721-726.
21. Cheng C.L., Kao Y.H., Lin S.J., et al. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf 2011, 20:236-242.
22. Cheng C.L., Lee C.H., Chen P.S., et al. Validation of acute myocardial infarction cases in the National Health Insurance Research Database in Taiwan. J Epidemiol 2014, 24:500-507.
23. Fine J.P., Gray R.J. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
24. Scirica B.M., Bhatt D.L., Braunwald E., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013, 369:1317-1326.
25. White W.B., Cannon C.P., Heller S.R., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013, 369:1327-1335.
26. Green J.B., Bethel M.A., Armstrong P.W., et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015, 373:232-242.
27. Leiter L.A., Teoh H., Braunwald E., et al. Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial. Diabetes Care 2015, 38:1145-1153.
28. Schernthaner G., Duran-Garcia S., Hanefeld M., et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: A randomized, controlled study (GENERATION). Diabetes Obes Metab 2015, 17:630-638.
29. Barzilai N., Guo H., Mahoney E.M., et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial. Curr Med Res Opin 2011, 27:1049-1058.
30. Barnett A.H., Huisman H., Jones R., et al. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: A randomised, double-blind, placebo-controlled trial. Lancet 2013, 382:1413-1423.
31. Schweizer A., Dejager S., Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: A 24-week, double-blind, randomized trial. Diabetes Obes Metab 2009, 11:804-812.
32. Marx N., Rosenstock J., Kahn S.E., et al. Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA(R)). Diab Vasc Dis Res 2015, 12:164-174.
33. Ussher J.R., Drucker D.J. Cardiovascular actions of incretin-based therapies. Circ Res 2014, 114:1788-1803.
34. Zhong J., Goud A., Rajagopalan S. Glycemia lowering and risk for heart failure: Recent evidence from studies of dipeptidyl peptidase inhibition. Circ Heart Fail 2015, 8:819-825.
35. Matsubara J., Sugiyama S., Sugamura K., et al. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J Am Coll Cardiol 2012, 59:265-276.
36. Group A.C., Patel A., MacMahon S., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
37. Gerstein H.C., Miller M.E., Byington R.P., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559. Action to Control Cardiovascular Risk in Diabetes Study Group.
38. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015, 373:198.